ACS Medicinal Chemistry Letters
Letter
thrombosis in mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 8674−
8679.
Funding
The authors are grateful to the NIH (R35GM122473 to J.A.E
and R01CA170741 to A.S.) for support of this work.
(14) Sun, B.; Dwivedi, N.; Bechtel, T. J.; Paulsen, J. L.; Muth, A.;
Bawadekar, M.; Li, G.; Thompson, P. R.; Shelef, M. A.; Schiffer, C. A.;
Weerapana, E.; Ho, I. C. Citrullination of NF- κB p65 promotes its
nuclear localization and TLR-induced expression of IL-1β and TNFα.
Sci. Immunol. 2017, 2, eaal3062.
Notes
The authors declare no competing financial interest.
(15) Li, P.; Yao, H.; Zhang, Z.; Li, M.; Luo, Y.; Thompson, P. R.;
Gilmour, D. S.; Wang, Y. M. Regulation of p53 target gene expression
by peptidylarginine deiminase 4. Mol. Cell. Biol. 2008, 28, 4745−4758.
(16) Chang, X.; Han, J.; Pang, L.; Zhao, Y.; Yang, Y.; Shen, Z.
Increased PADI4 expression in blood and tissues of patients with
malignant tumors. BMC Cancer 2009, 9, 40.
(17) Lewis, H. D.; Liddle, J.; Coote, J. E.; Atkinson, S. J.; Barker, M.
D.; Bax, B. D.; Bicker, K. L.; Bingham, R. P.; Campbell, M.; Chen, Y. H.;
Chung, C. W.; Craggs, P. D.; Davis, R. P.; Eberhard, D.; Joberty, G.;
Lind, K. E.; Locke, K.; Maller, C.; Martinod, K.; Patten, C.; Polyakova,
O.; Rise, C. E.; Ruediger, M.; Sheppard, R. J.; Slade, D. J.; Thomas, P.;
Thorpe, J.; Yao, G.; Drewes, G.; Wagner, D. D.; Thompson, P. R.;
Prinjha, R. K.; Wilson, D. M. Inhibition of PAD4 activity is sufficient to
disrupt mouse and human NET formation. Nat. Chem. Biol. 2015, 11,
189−191.
(18) Knuckley, B.; Jones, J. E.; Bachovchin, D. A.; Slack, J.; Causey, C.
P.; Brown, S. J.; Rosen, H.; Cravatt, B. F.; Thompson, P. R. A fluopol-
ABPP HTS assay to identify PAD inhibitors. Chem. Commun. 2010, 46,
7175−7177.
(19) Willis, V. C.; Gizinski, A. M.; Banda, N. K.; Causey, C. P.;
Knuckley, B.; Cordova, K. N.; Luo, Y.; Levitt, B.; Glogowska, M.;
Chandra, P.; Kulik, L.; Robinson, W. H.; Arend, W. P.; Thompson, P.
R.; Holers, V. M. N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-orni-
thine amide, a protein arginine deiminase inhibitor, reduces the severity
of murine collagen-induced arthritis. J. Immunol. 2011, 186, 4396−
4404.
ABBREVIATIONS
■
PAD, protein arginine deiminase; RA, rheumatoid arthritis;
ACPA, anticitrullinated protein antibodies; NET, neutrophil
extracellular trap; TNF, tumor necrosis factor alpha; IL-1β,
interleukin 1 beta; H4, histone 4
REFERENCES
■
(1) Fuhrmann, J.; Thompson, P. R. Protein arginine methylation and
citrullination in epigenetic regulation. ACS Chem. Biol. 2016, 11, 654−
668.
(2) Fuhrmann, J.; Clancy, K. W.; Thompson, P. R. Chemical biology
of protein arginine modifications in epigenetic regulation. Chem. Rev.
2015, 115, 5413−5461.
(3) Kearney, P. L.; Bhatia, M.; Jones, N. G.; Yuan, L.; Glascock, M. C.;
Catchings, K. L.; Yamada, M.; Thompson, P. R. Kinetic character-
ization of protein arginine deiminase 4: a transcriptional corepressor
Implicated in the onset and progression of rheumatoid arthritis.
Biochemistry 2005, 44, 10570−10582.
(4) Jones, J. E.; Causey, C. P.; Knuckley, B.; Slack-Noyes, J. L.;
Thompson, P. R. Protein arginine deiminase 4 (PAD4): current
understanding and future therapeutic potential. Curr. Opin. Drug
Discov. Devel. 2009, 12, 616−627.
(5) Bicker, K. L.; Thompson, P. R. The protein arginine deiminases:
structure, function, inhibition, and disease. Biopolymers 2013, 99, 155−
163.
(6) Taki, H.; Tomoharu, G.; Bryan, K.; Paul, R. T.; Oliver, V.; Kazuya,
H.; Tatsurou, M.; Kouichiro, S.; Hiroyuki, H.; Eiji, S. Purification of
enzymatically inactive peptidylarginine deiminase type 6 from mouse
ovary that reveals hexameric structure different from other dimeric
isoforms. Adv. Biosci. Biotechnol. 2011, 2, 304−310.
(7) Arita, K.; Hashimoto, H.; Shimizu, T.; Nakashima, K.; Yamada,
M.; Sato, M. Structural basis for Ca2+-induced activation of human
PAD4. Nat. Struct. Mol. Biol. 2004, 11, 777−783.
(20) Subramanian, V.; Knight, J. S.; Parelkar, S.; Anguish, L.;
Coonrod, S. A.; Kaplan, M. J.; Thompson, P. R. Design, synthesis, and
biological evaluation of tetrazole analogs of CI-Amidine as protein
arginine deiminase inhibitors. J. Med. Chem. 2015, 58, 1337−1344.
(21) Muth, A.; Subramanian, V.; Beaumont, E.; Nagar, M.; Kerry, P.;
McEwan, P.; Srinath, H.; Clancy, K.; Parelkar, S.; Thompson, P. R.
Development of a selective inhibitor of protein arginine deiminase 2. J.
Med. Chem. 2017, 60, 3198−3211.
(22) Jamali, H.; Khan, H. A.; Tjin, C. C.; Ellman, J. A. Cellular activity
of new small molecule protein arginine deiminase 3 (PAD3) inhibitors.
ACS Med. Chem. Lett. 2016, 7, 847−851.
(8) Witalison, E. E.; Thompson, P. R.; Hofseth, L. J. Protein arginine
deiminases and associated citrullination: physiological functions and
diseases associated with dysregulation. Curr. Drug Targets 2015, 16,
700−710.
(23) Jamali, H.; Khan, H. A.; Stringer, J. R.; Chowdhury, S.; Ellman, J.
A. Identification of multiple structurally distinct, nonpeptidic small
molecule inhibitors of protein arginine deiminase 3 using a substrate-
based fragment method. J. Am. Chem. Soc. 2015, 137, 3616−3621.
(24) Bendazac, niraparib, granisetron, pazopanib, axitinib, lonid-
amine, and lificiguat are approved drugs and drug candidates containing
the indazole heterocycle. Detailed information on these drugs including
compound structure, bioactivity, published studies, clinical trials,
applications, and usage can be obtained at PubChem (http://
(9) Koushik, S.; Joshi, N.; Nagaraju, S.; Mahmood, S.; Mudeenahally,
K.; Padmavathy, R.; Jegatheesan, S. K.; Mullangi, R.; Rajagopal, S.
PAD4: pathophysiology, current therapeutics and future perspective in
rheumatoid arthritis. Expert Opin. Ther. Targets 2017, 21, 433−447.
(10) Clark, S. R.; Ma, A. C.; Tavener, S. A.; McDonald, B.; Goodarzi,
Z.; Kelly, M. M.; Patel, K. D.; Chakrabarti, S.; McAvoy, E.; Sinclair, G.
D.; Keys, E. M.; Allen-Vercoe, E.; DeVinney, R.; Doig, C. J.; Green, F.
H. Y.; Kubes, P. Platelet TLR4 activates neutrophil extracellular traps to
ensnare bacteria in septic blood. Nat. Med. 2007, 13, 463−469.
(11) Villanueva, E.; Yalavarthi, S.; Berthier, C. C.; Hodgin, J. B.;
Khandpur, R.; Lin, A. M.; Rubin, C. J.; Zhao, W.; Olsen, S. H.; Klinker,
M.; Shealy, D.; Denny, M. F.; Plumas, J.; Chaperot, L.; Kretzler, M.;
Bruce, A. T.; Kaplan, M. J. Netting neutrophils induce endothelial
damage, infiltrate tissues, and expose immunostimulatory molecules in
systemic lupus erythematosus. J. Immunol. 2011, 187, 538−552.
(12) Ohlsson, S. M.; Ohlsson, S.; Soderberg, D.; Gunnarsson, L.;
Pettersson, A.; Segelmark, M.; Hellmark, T. Neutrophils from vasculitis
patients exhibit an increased propensity for activation by anti-
neutrophil cytoplasmic antibodies. Clin. Exp. Immunol. 2014, 176,
363−372.
(25) Mewshaw, R. E.; Zhou, D.; Zhou, P.; Shi, X. J.; Hornby, G.;
Spangler, T.; Scerni, R.; Smith, D.; Schechter, L. E.; Andree, T. H.
Studies toward the discovery of the next generation of antidepressants.
3. Dual 5-HT1A and serotonin transporter affinity within a Class of N-
aryloxyethylindolylalkylamines. J. Med. Chem. 2004, 47, 3823−3842.
(26) Cinelli, M. A.; Morrell, A.; Dexheimer, T. S.; Scher, E. S.;
Pommier, Y.; Cushman, M. Design, synthesis, and biological evaluation
of 14-substituted aromathecins as topoisomerase I inhibitors. J. Med.
Chem. 2008, 51, 4609−4619.
̀
(27) Bennetau, B.; Rajarison, F.; Dunogues, J.; Babin, P.
́
́
̀
Fonctionnalisation regioselective en position 2 de benzenes 1,3-
́
disubstitues. Tetrahedron 1993, 49, 10843−10854.
(13) Martinod, K.; Demers, M.; Fuchs, T. A.; Wong, S. L.; Brill, A.;
Gallant, M.; Hu, J.; Wang, Y. M.; Wagner, D. D. Neutrophil histone
modification by peptidylarginine deiminase 4 is critical for deep vein
(28) Mahiou, B.; Deinzer, M. L. Synthetic strategies in the preparation
of regiospecifically chlorine-37 labeled polychlorinated dibenzo-p-
diozins. J. Labelled Compd. Radiopharm. 1991, 31, 261−287.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX